Evidence map›Paper›PMID 33800799›Full record

ReviewInternational journal of molecular sciences2021

Liquid Biopsies in the Clinical Management of Germ Cell Tumor Patients: State-of-the-Art and Future Directions.

João Lobo, Ricardo Leão, Carmen Jerónimo, Rui Henrique

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. The utility of cfDNA in TGCT patient management: a systematic review.Therapeutic advances in medical oncology · 2022
    Review
  10. Article
  11. Review
  12. Improving outcomes in germ cell cancers using miRNA.Therapeutic advances in medical oncology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

João LoboCancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.ORCID 0000-0001-6829-1391
Ricardo LeãoFaculty of Medicine, University of Coimbra, Rua Larga, 3000-370 Coimbra, Portugal.ORCID 0000-0003-3719-717X
Carmen JerónimoCancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.ORCID 0000-0003-4186-5345
Rui HenriqueCancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.ORCID 0000-0003-3171-4666

Funding

Fundação para a Ciência e a Tecnologia PTDC/MEC-URO/ 29043/2017Fundação para a Ciência e a Tecnologia SFRH/BD/132751/2017
6 · The paper itself

Abstract

Liquid biopsies constitute a minimally invasive means of managing cancer patients, entailing early diagnosis, follow-up and prediction of response to therapy. Their use in the germ cell tumor field is invaluable since diagnostic tissue biopsies (which are invasive) are often not performed, and therefore only a presumptive diagnosis can be made, confirmed upon examination of the surgical specimen. Herein, we provide an overall review of the current liquid biopsy-based biomarkers of this disease, including the classical, routinely used serum tumor markers-the promising microRNAs rapidly approaching the introduction into clinical practice-but also cell-free DNA markers (including DNA methylation) and circulating tumor cells. Finally, and importantly, we also explore novel strategies and challenges for liquid biopsy markers and methodologies, providing a critical view of the future directions for liquid biopsy tests in this field, highlighting gaps and unanswered questions.

Indexed as

Liquid BiopsyBiomarkers, TumorCritical PathwaysDisease ManagementDNA, NeoplasmFemaleHumansMaleMicroRNAsNeoplasm ProteinsNeoplasms, Germ Cell and EmbryonalNeoplastic Cells, CirculatingOvarian NeoplasmsRNA, NeoplasmTesticular NeoplasmsBiomarkers, TumorDNA, NeoplasmMicroRNAsNeoplasm ProteinsRNA, Neoplasmbiomarkerscirculating tumor cellsdiagnosisDNA methylationfollow-upgerm cell tumorsliquid biopsiesmicroRNAsserum tumor markers

Identifiers

PMID33800799
PMCPMC7961393

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.